3 Columbus Circle
29 articles with Avenue Therapeutics
As of September 30, 2017, Avenue’s cash and short-term investments (certificates of deposit) totaled $26.1 million compared to $0.2 million at December 31, 2016, an increase of $25.9 million year-to-date.
Avenue Therapeutics Announces Dosing Of First Patient In Pivotal Phase III Clinical Trial Of Intravenous Tramadol For The Management Of Postoperative Pain
Avenue Therapeutics Announces Appointment Of Joseph Vazzano As Vice President Of Finance And Corporate Controller (Principal Financial And Accounting Officer)
Fortress Biotech Announces Appointment Of Lucy Lu, MD, As President And Chief Executive Officer Of Subsidiary Avenue Therapeutics
Avenue Therapeutics Receives Notice Of Allowance For A New Patent Application Covering Methods Of Administration For Intravenous Tramadol
Avenue Therapeutics Receives Notices Of Allowance For Patent Applications Covering Methods Of Administration For Intravenous Tramadol